Login to Your Account

Clinic Roundup

Monday, August 27, 2012

• Seattle Genetics Inc., of Bothell, Wash., initiated a Phase Ib trial evaluating SGN-75 in combination with everolimus (Afinitor, Novartis AG) in advanced metastatic renal cell carcinoma (RCC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription